AKT1 and lymphoma: In the same study, this was attributed to resistance due to high expression of mTORC2 and subsequent Akt and eIF4E phosphorylation.[11] Furthermore, Gupta et al have recently provided the first demonstration of antiproliferative and proapoptotic properties of a dual mTORC1/mTORC2 inhibitor in lymphoma through Akt pathway inhibition.[13] In the studies reported herein, we sought to understand the effect of CC214-1, a next-generation mTORC1/mTORC2 inhibitor on translation pathway associated with eIF4E.